215 related articles for article (PubMed ID: 14614026)
1. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Sabatino MA; Colombo T; Geroni C; Marchini S; Broggini M
Clin Cancer Res; 2003 Nov; 9(14):5402-8. PubMed ID: 14614026
[TBL] [Abstract][Full Text] [Related]
2. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
[TBL] [Abstract][Full Text] [Related]
3. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.
Lorusso D; Mainenti S; Pietragalla A; Ferrandina G; Foco G; Masciullo V; Scambia G
Expert Opin Investig Drugs; 2009 Dec; 18(12):1939-46. PubMed ID: 19938904
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
Caponigro F; Lorusso D; Fornari G; Barone C; Merlano M; Airoldi M; Schena M; MacArthur R; Weitman S; Jannuzzo MG; Crippa S; Fiorentini F; Petroccione A; Comis S
Cancer Chemother Pharmacol; 2010 Jul; 66(2):389-94. PubMed ID: 20480279
[TBL] [Abstract][Full Text] [Related]
5. Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.
Sabatino MA; Geroni C; Ganzinelli M; Ceruti R; Broggini M
Epigenetics; 2013 Jun; 8(6):656-65. PubMed ID: 23771052
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
Beria I; Baraldi PG; Cozzi P; Caldarelli M; Geroni C; Marchini S; Mongelli N; Romagnoli R
J Med Chem; 2004 May; 47(10):2611-23. PubMed ID: 15115402
[TBL] [Abstract][Full Text] [Related]
7. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.
Mathieu A; Remmelink M; D'Haene N; Penant S; Gaussin JF; Van Ginckel R; Darro F; Kiss R; Salmon I
Cancer; 2004 Oct; 101(8):1908-18. PubMed ID: 15386340
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
Clin Cancer Res; 2009 Jul; 15(13):4348-55. PubMed ID: 19509138
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
Kudoh S; Takada M; Masuda N; Nakagawa K; Itoh K; Kusunoki Y; Negoro S; Matsui K; Takifuji N; Morino H
Jpn J Cancer Res; 1993 Feb; 84(2):203-7. PubMed ID: 8385085
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
11. A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism.
Matsuba Y; Edatsugi H; Mita I; Matsunaga A; Nakanishi O
Cancer Chemother Pharmacol; 2000; 46(1):1-9. PubMed ID: 10912571
[TBL] [Abstract][Full Text] [Related]
12. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
13. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
14. Brostallicin: a new concept in minor groove DNA binder development.
Broggini M; Marchini S; Fontana E; Moneta D; Fowst C; Geroni C
Anticancer Drugs; 2004 Jan; 15(1):1-6. PubMed ID: 15090736
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Fujimoto S
Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
[TBL] [Abstract][Full Text] [Related]
16. Role of glutathione transferases in the mechanism of brostallicin activation.
Pezzola S; Antonini G; Geroni C; Beria I; Colombo M; Broggini M; Marchini S; Mongelli N; Leboffe L; MacArthur R; Mozzi AF; Federici G; Caccuri AM
Biochemistry; 2010 Jan; 49(1):226-35. PubMed ID: 19950984
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
18. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells.
Osaki S; Nakanishi Y; Takayama K; Pei XH; Ueno H; Hara N
Cancer Gene Ther; 2000 Feb; 7(2):300-7. PubMed ID: 10770640
[TBL] [Abstract][Full Text] [Related]
19. Lentinan enhances sensitivity of mouse colon 26 tumor to cis-diamminedichloroplatinum (II) and decreases glutathione transferase expression.
Murata T; Hatayama I; Kakizaki I; Satoh K; Sato K; Tsuchida S
Jpn J Cancer Res; 1996 Nov; 87(11):1171-8. PubMed ID: 9045947
[TBL] [Abstract][Full Text] [Related]
20. In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.
Tsunoda T; Tanimura H; Hotta T; Tani M; Iwahashi M; Ishimoto K; Tanaka H; Matsuda K; Yamaue H
J Surg Oncol; 2000 Jan; 73(1):6-11. PubMed ID: 10649271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
